{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Opus reports sustained vision gains as LCA5 gene therapy moves toward Phase 3 dosing","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/zeSoRaMFGO9fM7Vrea3IUu\" style=\"color:#fff;text-decoration:none;\">Opus reports sustained vision gains as LCA5 gene therapy moves toward Phase 3 dosing</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Opus Genetics reported sustained visual improvements in six participants receiving its experimental OPGx-LCA5 gene therapy, with follow-up through 24 months in three adults and six months in three ado...</p>\n    </blockquote>"}